Trial Profile
Lead Time of the Methotrexate Establishment and Vaccinal Protection Against the Pneumococcal Agent in Patients Affected With Rheumatoid Polyarthritis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Dec 2022
Price :
$35
*
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary) ; Pneumococcal vaccine
- Indications Pneumococcal infections
- Focus Pharmacodynamics; Registrational
- Acronyms VACIMRA
- 14 Nov 2022 Results assessing real impact of delaying initiation of MTX by 1 month on the outcome of RA at 1 year presented at the ACR Convergence 2022
- 04 Jun 2022 Results assessing the impact of delaying initiation of MTX by 1 month on the outcome of RA at 1 year presented at the 23rd Annual Congress of the European League Against Rheumatism
- 30 Jul 2020 Status changed from active, no longer recruiting to completed.